{
    "code": "60000964",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60000964",
    "time": "2021-09-10 05:53:04",
    "許可證字號": "衛部菌疫輸字第000964號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "113\/09\/09",
    "發證日期": "103\/09\/09",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA06000096402",
    "中文品名": "雅詩力 凍晶注射劑 50毫克",
    "英文品名": "ADCETRIS 50 mg powder for concentrate for solution for infusion",
    "適應症": "1.\t何杰金氏淋巴瘤\r\n(1)\t與doxorubicin、vinblastine和dacarbazine併用適用於先前未曾接受治療的CD30+第III期或第IV期何杰金氏淋巴瘤(HL) 成人病人。\r\n(2)\t適用於治療經自體幹細胞移植 (ASCT)後，高復發或惡化風險的CD30+ 何杰金氏淋巴瘤 (HL)成人病人。\r\n(3)\t適用於治療復發或頑固型 CD30+ 何杰金氏淋巴瘤 (HL)成人病人：\r\ni.\t已接受自體幹細胞移植 (ASCT)，或\r\nii.\t無法使用 ASCT 或多重藥物化療，且先前至少已接受兩種治療。\r\n2.\t周邊T細胞淋巴瘤\r\n(1)\t與cyclophosphamide、doxorubicin和prednisone併用適用於先前未曾接受治療之下列成人病人：\r\ni.\t全身性退行分化型大細胞淋巴瘤 (systemic anaplastic large cell lymphoma; sALCL)，或\r\nii.\t其他CD30+周邊T細胞淋巴瘤(PTCL)：包含血管免疫芽细胞性T细胞淋巴瘤(angioimmunoblastic T-cell lymphoma; AITL)及非特定周邊T細胞淋巴瘤(peripheral T-cell lymphoma, not otherwise specified; PTCL-NOS)。\r\n(2)\t適用於治療復發或頑固型全身性退行分化型大細胞淋巴瘤 (sALCL)成人病人。\r\n3.\t皮膚T細胞淋巴瘤\r\n(1)\t適用於先前至少已接受一種全身性治療的CD30+皮膚T細胞淋巴瘤(CTCL)成人病人。",
    "劑型": "243凍晶注射劑",
    "包裝": "50毫克玻璃小瓶裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "108\/09\/09",
    "主成分略述": "Brentuximab vedotin",
    "限制項目": "02輸　入 51免除銜接性臨床試驗",
    "申請商名稱": "1406701100  台灣武田藥品工業股份有限公司",
    "申請商地址": "台北市信義區松高路1號17樓",
    "主製造廠": [
        {
            "製造廠名稱": "FIT0479000  BSP PHARMACEUTICALS S.p.A",
            "製造廠廠址": "VIA APPIA KM 65,561, LATINA SCALO(LT), 04013, ITALY",
            "製造廠公司地址": "",
            "製造廠國別": "ITALY",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FAT0008000  TAKEDA AUSTRIA GMBH",
            "製造廠廠址": "ST. PETER-STRASSE 25 A-4020 LINZ, AUSTRIA",
            "製造廠公司地址": "",
            "製造廠國別": "AUSTRIA",
            "製程": "二級包裝廠"
        },
        {
            "製造廠名稱": "FGB0342000  PIRAMAL HEALTHCARE UK LIMITED",
            "製造廠廠址": "EARLS ROAD, GRANGEMOUTH STIRLINGSHIRE, FK3 8XG, UK",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED KINGDOM",
            "製程": "主成分(drug substance)製造廠"
        },
        {
            "製造廠名稱": "FIT0344000  DELPHARM NOVARA S.R.L.",
            "製造廠廠址": "VIA CROSA 86, 28065 CERANO (NOVARA), ITALY",
            "製造廠公司地址": "VIA VITTORINI, 129, 00144 ROMA, ITALY",
            "製造廠國別": "ITALY",
            "製程": "次包裝廠"
        },
        {
            "製造廠名稱": "FUS0850000  AbbVie Bioresearch Center",
            "製造廠廠址": "100 Research Drive, Worcester, MA 01605, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "主成分(drug substance)製造廠"
        },
        {
            "製造廠名稱": "FUS0877000  SAFC INC.",
            "製造廠廠址": "645 SCIENCE DRIVE, MADISON, WI 53711, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "主成分(drug substance)製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013004310",
            "成分名稱": "Brentuximab vedotin",
            "含量描述": "",
            "含量": "50.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "TW Chinese PI_ADCETRIS_Extravasation ADR_(clean) - 202107-110-07-22.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000964&Seq=011&Type=9"
        },
        {
            "title": "6115517-01 LA Adcetris 50 mg TWN.101x32mm.2. print-104-09-29(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60000964&Seq=006&Type=8"
        }
    ]
}